Cartesian Therapeutics, Inc. - Common Stock RNAC 深 滬
等待開盤 08-28 09:30:00 美东时间
10.625
-0.155
-1.44%
華盛通- 最 高10.83
- 今 開10.68
- 成交量 3.69万股
- 最 低 10.5181
- 昨 收 10.78
- 總市值 2.76亿
- 52周最高 26.50
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 8.46
- 委 比 -33.33%
- 總股本 2595.43万
- 歷史最高 840.00
- 量 比 0.71
- 振 幅 2.89%
- 歷史最低 8.46
- 每 手 1
- 風險率 6.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cartesian Therapeutics to Participate in Upcoming Investor Conferences
<p>Cartesian Therapeutics announced its management will participate in three investor conferences in September 2025. The events include fireside chats at Cantor Global Healthcare Conference and Morgan Stanley’s Annual Healthcare Conference, and a presentation at the H.C. Wainwright Global Investment Conference. Live webcasts and replays will be available on the company’s website. About Cartesian Therapeutics, the Company is focused on cell therap...
今天 11:00
Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.82) by 160.98 percent. This is a 7.41 percent decrease over earnings of $0.54 per share
08-07 19:20
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.
07-25 01:08
Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38
Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.
07-09 18:55
Cartesian Therapeutics Holds Annual Stockholders Meeting
Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On June 13, 2025...
06-16 19:28
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, a clinical-stage biotech company, announced the granting of inducement awards to three new employees, including options to purchase 26,350 shares with an exercise price of $9.98 under its 2018 Employment Inducement Incentive Award Plan. The options vest 25% on June 2, 2026, followed by three equal annual installments, fully vesting by 2029, with a 10-year term. The company is focused on pioneering cell therapy for autoimmu...
06-03 11:05
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
Cartesian Therapeutics has啟動其Descartes-08的三期AURORA試驗，這是針對全身性重症肌无力的首款CAR-T療法。首位患者已入組，將評估其療效及安全性。Descartes-08無需預處理化療，適用於門診治療。該療法已在二期研究中展示出持久的應答，平均MG-ADL評分改善顯著。試驗將隨機對照，規模約100例患者，主要終點為三個月時的評分改善情況。公司หวัง藉此改進現有的MG治療方案，提供更安全、持久的選擇。
05-30 11:00
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.
05-28 03:42
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
